# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060075
Filing Date
2024-05-15
Accepted
2024-05-15 08:57:34
Documents
52
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | tcrt-20240331.htm iXBRL | 10-Q | 1229545
2 | EX-10.1 | tcrt-ex10_1.htm | EX-10.1 | 669
3 | PDF COURTESY COPY | tcrt-ex10_1.pdf | EX-10.1 | 203180
4 | EX-31.1 | tcrt-ex31_1.htm | EX-31.1 | 12814
5 | EX-32.1 | tcrt-ex32_1.htm | EX-32.1 | 7013
| Complete submission text file | 0000950170-24-060075.txt |  | 5210656

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | tcrt-20240331.xsd | EX-101.SCH | 963077
55 | EXTRACTED XBRL INSTANCE DOCUMENT | tcrt-20240331_htm.xml | XML | 494708

Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33038 | Film No.: 24947421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)